GRACE JABLONSKI: Open Payments
NPI 1467201350 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,357 in 61 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $846 · 2025 $1,357
Food & beverage: $1,357
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $340 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $220 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $215 |
| Ardelyx, Inc. | 9 | $196 |
| Gilead Sciences, Inc. | 7 | $160 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 1 | $35 |
| Lilly USA, LLC | 1 | $29 |
| Novo Nordisk Inc | 1 | $23 |
Products named: XIFAXAN, IBSRELA, ENTYVIO, LINZESS, RINVOQ, SKYRIZI, REZDIFFRA, GATTEX.
Industry payments across RI — which companies pay providers there.
